抑制尿酸合成药物的疗效与安全性评价

被引：12

作者：

杜娜

王颜刚

机构：

[1] 青岛大学附属医院内分泌代谢科

来源：

药品评价 | 2015年 / 12卷 / 07期

关键词：

痛风; 别嘌醇; 非布司他; 疗效; 安全性;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100706 [药理学];

摘要：

痛风是一种单尿钠酸盐在关节及其周围组织等部位沉积所致的晶体相关性疾病,与嘌呤代谢紊乱及(或)尿酸排泄减少所致的高尿酸血症直接相关。随着我国人民生活水平的提高、饮食结构的改变,痛风的发病率有逐年增高的趋势。降尿酸治疗对于高尿酸血症和痛风患者至关重要。本文简要介绍抑制尿酸合成药物的作用机制、疗效及安全性评价。

引用

页码：50 / 54

页数：5

共 13 条

[1]

Cardiovascular thromboembolic events associated with febuxostat: Investigation of cases from the FDA adverse event reporting system database [J].

Gandhi, Pranav K. ;

Gentry, William M. ;

Bottorff, Michael B. .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2013, 42 (06) :562-566

[2]

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia [J].

Khanna, Dinesh ;

Fitzgerald, John D. ;

Khanna, Puja P. ;

Bae, Sangmee ;

Singh, Manjit K. ;

Neogi, Tuhina ;

Pillinger, Michael H. ;

Merill, Joan ;

Lee, Susan ;

Prakash, Shraddha ;

Kaldas, Marian ;

Gogia, Maneesh ;

Perez-Ruiz, Fernando ;

Taylor, Will ;

Liote, Frederic ;

Choi, Hyon ;

Singh, Jasvinder A. ;

Dalbeth, Nicola ;

Kaplan, Sanford ;

Niyyar, Vandana ;

Jones, Danielle ;

Yarows, Steven A. ;

Roessler, Blake ;

Kerr, Gail ;

King, Charles ;

Levy, Gerald ;

Furst, Daniel E. ;

Edwards, N. Lawrence ;

Mandell, Brian ;

Schumacher, H. Ralph ;

Robbins, Mark ;

Wenger, Neil ;

Terkeltaub, Robert .

ARTHRITIS CARE & RESEARCH, 2012, 64 (10) :1431-1446

[3]

Uric acid and high sensitive C-reactive protein are associated with subclinical thoracic aortic atherosclerosis.[J]..Journal of Cardiology.2012,

[4]

Elevated Serum Uric Acid Predicts Chronic Kidney Disease [J].

Yamada, Tamaki ;

Fukatsu, Mitsuru ;

Suzuki, Sadao ;

Wada, Tsuneya ;

Joh, Takashi .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 342 (06) :461-466

[5]

Gout therapeutics: new drugs for an old disease [J].

Burns, Christopher M. ;

Wortmann, Robert L. .

LANCET, 2011, 377 (9760) :165-177

[6]

Placebo-Controlled; Double-Blind Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia Including Those With Gout in Japan: Phase 3 Clinical Study.[J].Kamatani Naoyuki;Fujimori Shin;Hada Toshikazu;Hosoya Tatsuo;Kohri Kenjiro;Nakamura Toshitaka;Ueda Takanori;Yamamoto Tetsuya;Yamanaka Hisashi;Matsuzawa Yuji.Journal of Clinical Rheumatology.2011, 4 Su

[7]

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population.[J].Wichittra Tassaneeyakul;Thawinee Jantararoungtong;Pei Chen;Pao-Yu Lin;Somsak Tiamkao;Usanee Khunarkornsiri;Pachadaporn Chucherd;Parinya Konyoung;Suda Vannaprasaht;Charoen Choonhakarn;Pornrith Pisuttimarn;Alisara Sangviroon;Wongwiwat Tassaneeyakul.Pharmacogenetics and Genomics.2009, 9

[8]

Use of Allopurinol in Slowing the Progression of Renal Disease Through Its Ability to Lower Serum Uric Acid Level.[J].Yui-Pong Siu;Kay-Tai Leung;Matthew Ka-Hang Tong;Tze-Hoi Kwan.American Journal of Kidney Diseases.2005, 1

[9]

Selectivity of febuxostat; a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.[J].Yasuhiro Takano;Kumiko Hase-Aoki;Hideki Horiuchi;Lin Zhao;Yoshinori Kasahara;Shiro Kondo;Michael A. Becker.Life Sciences.2004, 16

[10]

Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice [J].

Horiuchi, H ;

Ota, M ;

Nishimura, S ;

Kaneko, H ;

Kasahara, Y ;

Ohta, T ;

Komoriya, K .

LIFE SCIENCES, 2000, 66 (21) :2051-2070

← 1 2 →